Showing 6521-6530 of 7509 results for "".
- Alastin Skincare Launches Restorative Neck Complexhttps://practicaldermatology.com/news/alastin-skincare-launches-restorative-neck-complex/2457916/Alastin Skincare, Inc. has incorporated its proven, proprietary TriHex Technology into a new product designed for the specific needs of the neck and décolletage: Restorative Neck Complexwith TriHex Technology. This breakthrough treatment is formulated to addr
- Research Elucidates LIGHT's Role in ADhttps://practicaldermatology.com/news/research-elucidates-lights-role-in-ad/2457919/LIGHT, a member of the tumor necrosis factor (TNF) super family, directly controls the hyperproliferation of keratinocytes as well as the expression of periostin, a protein that contributes to the clinical features of atopic dermatitis and other inflammatory skin diseases such as scleroderma, rep
- New from Nerium: Prolistic Probiotic Productshttps://practicaldermatology.com/news/new-from-nerium-prolistic-probiotic-products/2457921/Nerium International is rolling out Prolistic™ Pre & Probiotic Plus Vitamins powder packets and Prolistic™Skin-Balancing Lotion with Probiotic Technology. The new Prolistic Pre & Probiotic Plus Vitamins powder
- Cochrane Review: Biologics Trump Other Systemics for Psohttps://practicaldermatology.com/news/cochrane-review-biologics-trump-other-systemic-meds-for-pso/2457924/Biologics appear to be the most effective systemic medicines for achieving a chronic plaque psoriasis score of PASI (Psoriasis Area and Severity Index) 90, according to a newly published Cochrane Revie
- Desmoplastic Melanoma May Be Highly Responsive to Anti-PD-1/PD-L1 Therapieshttps://practicaldermatology.com/news/desmoplastic-melanoma-may-be-highly-responsive-to-anti-pd-1pd-l1-therapies/2457926/Patients with desmoplastic melanoma are more responsive to immune-activating anti-PD-1/PD-L1 therapies than previously assumed, Moffitt Cancer Center researchers report in the Jan. 10 issue of Nature. Pembrolizumab and niv
- FDA Grants AbbVie's Upadacitinib Breakthrough Therapy Designation for Atopic Dermatitishttps://practicaldermatology.com/news/fda-grants-abbvies-upadacitinib-breakthrough-therapy-designation-for-atopic-dermatitis/2457932/The FDA granted Breakthrough Therapy Designation for AbbVie's investigational, once-daily oral JAK1-selective inhibitor upadacitinib (ABT-494) in adult patients with moderate to severe atopic dermatitis who are candidates for systemic therapy. This Breakthrough Therapy Designation is supporte
- New AD Yardstick Highlights Treatment Advanceshttps://practicaldermatology.com/news/new-ad-yardstick-highlights-treatment-advances/2457933/Treatment for atopic dermatitis (AD) has changed a lot in the last few years, according to a new yardstick published in Annals of Allergy, Asthma and Immunology. “The Atopic Dermatitis Yardstick
- Scientific First: Researchers Grow Hairy Skin In A Dishhttps://practicaldermatology.com/news/scientific-first-researchers-grow-hairy-skin-in-a-dish/2457934/Indiana University School of Medicine researchers have successfully developed a method to grow hairy skin from mouse pluripotent stem cells—a discovery that could lead to new approaches to model disease and new therapies for the treatment of skin disorders and cancers. This res
- Med Spas on Fleek with Millennialshttps://practicaldermatology.com/news/med-spas-on-fleek-with-millennials/2457940/Younger generations are driving the med spa boom, according to a new American Med Spa Association (AmSpa) study. The medical spa industry is one of the fastest developing in the US, with revenues growing at a double-digit pace since 2010, and by more than 20 percent each year since 2013.
- BridgeBio Pharma Appoints Drs. Sanuj Ravindran and Eric Michael David as CEOs-in-Residence to Lead Dermatology and Gene Therapy Programshttps://practicaldermatology.com/news/bridgebio-pharma-appoints-drs-sanuj-ravindran-and-eric-michael-david-as-ceos-in-residence-to-lead-dermatology-and-gene-therapy-programs/2457942/BridgeBio Pharma, a clinical-stage biopharmaceutical company, today announced that it has strengthened its executive leadership team with two key hires who will join the company as CEOs-in-residence. Sanuj Ravindran, MD, will serve as CEO of PellePharm, Inc. and wil